Drug Profile
Research programme: selective estrogen receptor modulators - Ligand/Pfizer
Alternative Names: Research programme: SERMs - Ligand/Pfizer; Selective estrogen receptor modulators - Abbot/Pfizer; SERMs research programme - Ligand/PfizerLatest Information Update: 07 Feb 2001
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals; Pfizer
- Class Small molecules
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Breast cancer; Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 07 Feb 2001 Discontinued-Preclinical for Alzheimer's disease in USA (Unknown route)
- 07 Feb 2001 Discontinued-Preclinical for Breast cancer prevention in USA (Unknown route)
- 07 Feb 2001 Discontinued-Preclinical for Breast cancer treatment in USA (Unknown route)